SCHEMBL3879707

SCHEMBL3879707

COC(=O)c1cccc(CN(C)S(=O)(=O)c2cc3ccccc3s2)c1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.53
LOXL2 Q9Y4K0 1/20 0.44
NR3C1 P04150 1/20 0.44
CYP4F2 P78329 2/20 0.43
CYP4A11 Q02928 2/20 0.43
SQLE Q14534 1/20 0.43
MAPT P10636 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
RXFP1 Q9HBX9 3/20 0.41
LMNA P02545 3/20 0.41
HDAC4 P56524 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
NPC1 O15118 1/20 0.40
RECQL P46063 1/20 0.40
LOX P28300 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3880937 0.89 RAB9A (0.52) RAB9AMAPTSMN1; SMN2KDM4EALDH1A1
SCHEMBL3886237 0.88 TRPM8 (0.49) SQLEMAPTSMN1; SMN2ALDH1A1RXFP1
SCHEMBL3872157 0.84 PPARG (0.45) RAB9ASQLEMAPTSMN1; SMN2ALDH1A1
SCHEMBL3887293 0.82 MAPT (0.49) RAB9AMAPTSMN1; SMN2KDM4EALDH1A1
SCHEMBL3876863 0.81 NR1H4 (0.49) RAB9AMAPTSMN1; SMN2KDM4EALDH1A1
SCHEMBL3872649 0.81 ALDH1A1 (0.49) RAB9ASMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL3874272 0.81 POLB (0.49) RAB9ALOXL2CYP4F2CYP4A11MAPT
SCHEMBL3872970 0.80 ROCK2 (0.45) RAB9AMAPTSMN1; SMN2KDM4EALDH1A1
SCHEMBL3882723 0.79 ALDH1A1 (0.51) SMN1; SMN2ALDH1A1LMNAHDAC6NPC1
SCHEMBL3877752 0.79 PLAU (0.54) RAB9ALOXL2NR3C1CYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814846-B1 11BETA-HSD1 INHIBITORS EVOTEC AG (DE) 2009-04-08 EP disclosed
US-20090069323-A1 11beta-hsdi inhibitors EVOTEC AG (DE) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069323-A1 11beta-hsdi inhibitors HSD3B1, HSD3B2, HSD11B1 RAB9A 4300/4885LOXL2 2990/4885NR3C1 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.